Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Google Disrupts Major Residential Proxy Network IPIDEA 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
The Maire - EuroChem Case: Three Lessons for Global Business 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
LOS ANGELES, May 23, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) for possible violations of federal securities laws between May 1, 2012 and December 11, 2013 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 was going well and the share price was artificially inflated. Upon release of this news, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
